Skip Nav Destination
1-5 of 5
Caitlin L. Costello, MD, Benjamin Brookhart, Matthew J. Wieduwilt, MD PhD, Nina Shah, MD, Carolyn Mulroney, MD, Edward D. Ball, MD
Blood (2020) 136 (Supplement 1): 5–6.
Michael Scordo, MD, Lihua E Budde, MD PhD, Mehrdad Abedi, MD, Carolyn Mulroney, MD, Bita Fakhri, MDMPH, Attaphol Pawarode, MDPhD, Bhagirathbhai Dholaria, MBBS, Edward Kavalerchik, MD, Sanjay K. Aggarwal, MD, Muzaffar H. Qazilbash, MD, Paul Finnegan, MD, Sergio A. Giralt, MD
Blood (2020) 136 (Supplement 1): 14–15.
Aaron M Goodman, MD, Kimberly A Holden, Ah-Reum Jeong, MD, Lisa Kim, Kerry D Fitzgerald, PhD, Eyad Almasri, PhD, Graham McLennan, Marcia Eisenberg, PhD, Amin H Jahromi, Carl Hoh, Michael Hurley, Carolyn Mulroney, MD, Dimitrios Tzachanis, MD PhD, Edward D. Ball, MD, Taylor J Jensen, PhD BS, Razelle Kurzrock, MD
Blood (2020) 136 (Supplement 1): 17.
Blood (2019) 134 (Supplement_1): 3117.
A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401
Matthew J. Wieduwilt, MD PhD, Brian A. Jonas, MD, Gary J. Schiller, MD, Lin Liu, PhD, Carolyn Mulroney, MD, Gabriel N. Mannis, MD, Dimitrios Tzachanis, MD PhD, Januario E. Castro, MD, Edward D Ball, MD, Peter T. Curtin, MD, Charalambos Andreadis, MD, Aaron C. Logan, MD PhD, Jesika Reiner, MPH, Lloyd E. Damon, MD
Blood (2018) 132 (Supplement 1): 4018.